Eli Lilly & Company (NYSE:LLY) ranks among the best low volatility stocks to buy according to analysts. On July 11, Guggenheim reiterated its Buy rating on Eli Lilly & Company ahead of the company’s second-quarter earnings report and increased its price target from $936 to $942.
Pixabay/Public Domain
In contrast to the consensus predictions of $4.39 billion from VisibleAlpha and $4.89 billion from FactSet, the firm projects second-quarter Mounjaro sales of $4.49 billion. Guggenheim also predicts that Zepbound will rake in $3.10 billion in US sales in the second quarter, which is marginally more than the $2.94 billion consensus estimate.
Guggenheim’s modified model also takes into account a projected $0.14 effect on earnings per share from second-quarter IPR&D, as well as improved tirzepatide expectations based on prescription analysis.
The firm also emphasized that investors are paying close attention to net price and prescription trends for tirzepatide, as well as a number of important clinical trial readouts scheduled through the end of 2025.
Eli Lilly & Company is a major global pharmaceutical company that develops, manufactures, and distributes a wide range of drugs. Founded in 1876, it has grown to become one of the world’s largest pharmaceutical companies.
Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds
